News
Together with the World Health Organization (WHO), The Netherlands will organise a global conference in April 2019 about the fight against antibiotic resistance.
Read moreMadam Therapeutics, a privately-held biotech company that is developing a novel class of antibiotics inspired by the defense mechanisms of the human body, today announced the closing of its first financing round of 1,1M EUR.
Read moreOn the 22nd of May, alongside the annual World Health Assembly in Geneva the Global Antimicrobial Resistance and Development Hub (Global AMR R&D Hub) was launched.
Read moreThe UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.
Read more
NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated the column “Company in the spotlight” issue. In our second edition, we speak with Dr. Hans Platteeuw, founder and CEO of Avivia B.V., a Nijmegen based company that supports pharmaceutical development for new and existing drugs including drug repurposing and reformulation.
Read moreResearchers from the Leiden University Medical Center (LUMC), Academic Medical Center (AMC) and the Association of Dutch Burn Centers have published on the use of antimicrobial peptide SAAP-148 to combat drug-resistant bacteria and biofilms in the latest edition of the scientific journal Science Translational Medicine.
Read more
The Belgian Health Care Knowledge Centre (KCE) and ZonMw, the Netherlands Organisation for Health Research and Care innovation, invest a maximum of 6 million euros in a joint programme under the name ‘BeNeFIT’.
Read more
Almost fifty scientists and twenty companies will work on the development of new antibiotics and alternatives to antibiotics, which must become available for the healthcare system for a fair and affordable price. The research is done in eight projects that have received the green light from NWO Domain Applied and Engineering Sciences (AES). Together with the Ministry of Health, Welfare and Sport (VWS), NWO invests almost 7 million euros in the research programme.
Read more
NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated the column“Company in the spotlight” issue. In this first edition, we speak with Dr. Andreas Bastian, the CEO of AGILeBiotics B.V. This antimicrobial developing company was founded earlier this year and is a perfect candidate to kick-off this topic!
Read more
Five projects awarded in NWO-CCC partnership program focusing on beneficial effects of carbohydrates
The five awarded projects will investigate the beneficial effects of carbohydrates on microorganisms in the gastro-intestinal tract. The results are expected to aid in the reduction of antibiotics use in humans and farm animals. A total of 2.5 million Euros is invested in these projects, including contributions of TKI Agri&Food, Avebe, FrieslandCampina and NutritionSciences.
Read more